96
Participants
Start Date
October 15, 2025
Primary Completion Date
April 15, 2026
Study Completion Date
June 30, 2026
Independent use of the Mobili® Device by patients, overseen by pharmacists
"After recruitment each participant will be subject to a type I medication review.~After allocation to the intervention group, pharmacists will provide initial training to participants, and during the course of the intervention whenever necessary (e.g. when delivering the eDosette with the therapeutic regime). Pharmacists will prepare the eDosette in the pharmacy and deliver it directly to participants with no further intervention.~Participants will receive the number of eDosettes their therapeutic regime allows, to minimize visits to the pharmacy. For the control group, pharmacists will also provide the number of DAAs the therapeutic regime allows. Upon finishing the intervention, a new type II medication review will be performed for all participants (intervention and control) and information related to their personal therapeutic regime will be provided, ensuring a safe exit of the study."
Universidade Lusófona - Centro Universitário de Lisboa, Lisbon
CBIOS - Research Center for Biosciences & Health Technologies
UNKNOWN
MedThings
UNKNOWN
Associação Nacional das Farmácias
UNKNOWN
University of Oslo
OTHER
Universidade de Trás-os-Montes e Alto Douro
UNKNOWN
GHTM - Global Health and Tropical Medicine
UNKNOWN
COFAC Cooperativa de Formacao e Animacao Cultural CRL (Portugal)
UNKNOWN
Lusofona University
OTHER